GET THE APP

Drug repurposing screen for rapid identification of therapeutics | 18133
Journal of Genetic Syndromes & Gene Therapy

Journal of Genetic Syndromes & Gene Therapy
Open Access

ISSN: ISSN: 2157-7412

+44 1223 790975

Drug repurposing screen for rapid identification of therapeutics for zika virus infection


2nd World Congress on Rare Diseases and Orphan Drugs

June 29-30, 2017 London, UK

Wei Zheng

National Institutes of Health, USA

Scientific Tracks Abstracts: J Genet Syndr Gene Ther

Abstract :

Zika virus infection with complications of microcephaly and other complications has emerged as a health threat in many countries where the infection has been reported in over 60 countries. Vaccines and therapeutics are currently unavailable for the Zika virus infection. We have developed several compound screening assays and carried out the drug repurposing screens to identify potential therapeutics for the Zika virus infection. The newest results on drug repurposing screens and Zika virus drug development will be presented in this talk.

Biography :

Wei Zheng received his PhD in Pharmacology from the State University of New York at Buffalo. He had worked for 12 years in pharmaceutical companies (Berlex, Amgen, and Merck) for drug discovery and development. Since 2005, he has worked at National Institutes of Health for development of therapeutics for rare and neglected diseases. He has identified several drugs from drug repurposing screens and advanced two of them to clinical trials. Currently, he is working on the therapeutics development for lysosomal storage diseases, drug resistant cancer and infectious diseases.

Email: wei.zheng@nih.gov

Top